Top Companies in the mRNA Vaccines and Therapeutics Market

Astrazeneca, Pfizer, Inc., Sangamo Therapeutics, Moderna, Inc., Sanofi, Argos Therapeutics, GlaxoSmithKline plc., Gennova Biopharmaceuticals Limited, DAIICHI SANKYO COMPANY, LIMITED., Boehringer Ingelheim International GmbH are leading the global mRNA vaccines and therapeutics market.

The global mRNA vaccines and therapeutics market was valued at USD 64.5 billion in 2023, driven by the rising incidence of chronic diseases and increasing awareness of the widespread potential of mRNA technology across the globe. The market is expected to grow at a CAGR of 1.20% during the forecast period of 2024-2032, with the values to reach USD 71.7 billion by 2032.

mRNA vaccines and therapeutics utilise messenger RNA molecules to instruct cells to produce proteins that trigger immune responses or treat diseases. The mRNA vaccines and therapeutics market is anticipated to be driven by factors such as the rising prevalence of chronic diseases and the rapid development of mRNA vaccines. The rising number of research and development initiatives and the increasing number of approvals by the regulatory authorities are strengthening the market demand.

Some common trends driving the market growth include technological advancements enabling enhanced development of new and improved mRNA therapeutics. With the launch of high-end mRNA delivery systems along with the use of effective formulation techniques and manufacturing processes, the market is poised to find more stability in the coming years. Personalised medicines are encountering heightened demand propelling the market growth. The market is further influenced by the investment activities taking place, solidifying the presence of mRNA vaccines and therapeutics.

The market is witnessing various research activities aimed at exploring expanded application areas of mRNA vaccines and therapeutics. For instance, in May 2024, a group of researchers at the University of Florida performed first-ever human clinical trial of four adult patients. It was found amusing how the mRNA cancer vaccine developed by the University of Florida instantly manipulated the immunity system of the patients to attack the most aggressive and fatal brain tumour, glioblastoma. The success of this clinical trial has led the UF Health Cancer Center researchers to now test it in a Phase 1 pediatric clinical trial for brain cancer.

 
Top Companies Leading the mRNA Vaccines and Therapeutics Market in 2024

1.    AstraZeneca

AstraZeneca is a multinational pharmaceutical and biotechnology company specialising in oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company played a pivotal role in battling COVID-19 by developing the Oxford-AstraZeneca COVID-19 vaccine showcasing their efforts toward developing an innovative vaccine solution.

2.    Pfizer, Inc.

Pfizer is a multinational pharmaceutical and biotechnology corporation. The company specialises in medicine and vaccine development in immunology, oncology, cardiology, endocrinology, and neurology. Pfizer established a partnership with BioNTech and developed the first widely approved mRNA COVID-19 vaccine, Comirnaty.

3.    Sangamo Therapeutics

Sangamo Therapeutics is a biotechnology company focused on developing gene therapy, gene editing, and cell therapies for the treatment of rare diseases. The company is not a major player in mRNA vaccines domain however it plays a crucial role in a wider mRNA therapeutics landscape.

4.    Moderna, Inc.

Moderna is a pharmaceutical and biotechnology company with a major focus on RNA therapeutics, primarily mRNA vaccines. With only one commercial product Moderna COVID-19 vaccine in its portfolio, the company stands strong in the mRNA vaccines and therapeutics market. In a press release in July 2024, the U.S. Department of Health and Human Services (HHS) said that they have decided to fund Moderna with USD 176 million, through the Biomedical Advanced Research and Development Authority (BARDA) for the development of an mRNA-based pandemic influenza vaccine.

 
5.    Sanofi

Sanofi is a French multinational pharmaceutical and healthcare company focused on developing treatments for diabetes, cardiovascular diseases, rare diseases, multiple sclerosis, and vaccines. The company has major plans to enhance its capabilities in innovative vaccine solutions.

6.    Gennova Biopharmaceuticals Limited

Gennova Biopharmaceuticals is an Indian biotechnology company dedicated to research, development, production, and commercialisation of bio-therapeutics and vaccines to address fatal diseases. The company is successfully pioneering mRNA vaccine development in India with its COVID-19 vaccine, GEMCOVAC-19.

7.    GlaxoSmithKline plc.

They are exploring mRNA technology through collaborations, aiming to enhance their vaccine development. GSK's role in the mRNA market includes efforts to innovate next-generation vaccines, particularly for infectious diseases.

8.    DAIICHI SANKYO COMPANY, LIMITED.

Daiichi Sankyo, headquartered in Tokyo, Japan, specializes in oncology, cardiovascular, and rare diseases. They are engaged in mRNA vaccine development through partnerships and internal research. Daiichi Sankyo's involvement in the mRNA market emphasizes its commitment to innovative therapeutic approaches.